ICON Public Limited Company (ICLR) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

ICON Public Limited Company (ICLR) closed at USD 175.13 on 2026-10-15, a change of +5.5 % over the past year, with a market capitalization of USD 13.13B.

ICON Public Limited Company recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ICON Public Limited Company key figures

Previous close

USD 175.13 (2026-10-15)

1-year change

+5.5 %

Market cap

USD 13.13B

Enterprise value

USD 15.73B

P/E ratio (trailing)

179.14

P/E ratio (forward)

14.44

EPS (trailing)

0.95

EPS (forward)

11.78

PEG ratio

0.53

Price to book

1.40

Revenue growth

1.2 %

Earnings growth

-63.3 %

Dividend per share (trailing)

0.00

Short ratio

2.69

Employees

40,200

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ICON Public Limited Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ICON Public Limited Company and compare it with other stocks.